Literature DB >> 17979655

Prediction of intestinal first-pass drug metabolism.

Jiansong Yang1, Masoud Jamei, Karen Rowland Yeo, Geoffrey T Tucker, Amin Rostami-Hodjegan.   

Abstract

Despite a lower content of many drug metabolising enzymes in the intestinal epithelium compared to the liver (e.g. intestinal CYP3A abundance in the intestine is 1% that of the liver), intestinal metabolic extraction may be similar to or exceed hepatic extraction. Modelling of events on first-pass through the intestine requires attention to the complex interplay between passive permeability, active transport, binding, relevant blood flows and the intrinsic activity and capacity of enzyme systems. We have compared the predictive accuracy of the "well-stirred" gut model with that of the "Q(Gut)" model. The former overpredicts the fraction escaping first-pass gut metabolism; the latter improves the predictions by accounting for interplay between permeability and metabolism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17979655     DOI: 10.2174/138920007782109733

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  82 in total

1.  A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Authors:  Karthik Venkatakrishnan; Michael D Pickard; Lisa L von Moltke
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

3.  Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

Authors:  Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh
Journal:  Pharm Res       Date:  2012-03-14       Impact factor: 4.200

4.  Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.

Authors:  Eleanor J Guest; Karen Rowland-Yeo; Amin Rostami-Hodjegan; Geoffrey T Tucker; J Brian Houston; Aleksandra Galetin
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

Review 5.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

6.  Comment on: "A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood".

Authors:  Guo-Fu Li; Xiao Gu; Guo Yu; Shui-Yu Zhao; Qing-Shan Zheng
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

7.  The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models.

Authors:  Emile P Chen; Guoying Tai; Harma Ellens
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

8.  Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.

Authors:  Weize Huang; Mariko Nakano; Jennifer Sager; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2017-08-31       Impact factor: 3.922

9.  Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.

Authors:  Ruben de Kanter; Patricia N Sidharta; Stéphane Delahaye; Carmela Gnerre; Jerome Segrestaa; Stephan Buchmann; Christopher Kohl; Alexander Treiber
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

Review 10.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.